Skip to main content
Erschienen in: Clinical and Experimental Nephrology 1/2010

01.02.2010 | Review Article

Cardiorenal syndrome: still not a defined entity

verfasst von: Carlo Longhini, Christian Molino, Fabio Fabbian

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Because of the increasing incidence of cardiac failure and chronic renal failure due to the progressive aging of the population, the extensive application of cardiac interventional techniques, the rising rates of obesity and diabetes mellitus, coexistence of heart failure and renal failure in the same patient are frequent. More than half of subjects with heart failure had renal impairment, and mortality worsened incrementally across the range of renal dysfunctions. In patients with heart failure, renal dysfunction can result from intrinsic renal disease, hemodynamic abnormalities, or their combination. Severe pump failure leads to low cardiac output and hypotension, and neurohormonal activation produces both fluid retention and vasoconstriction. However, the cardiorenal connection is more elaborate than the hemodynamic model alone; effects of the renin-angiotensin system, the balance between nitric oxide and reactive oxygen species, inflammation, anemia and the sympathetic nervous system should be taken into account. The management of cardiorenal patients requires a tailored therapy that prioritizes the preservation of the equilibrium of each individual patient. Intravascular volume, blood pressure, renal hemodynamic, anemia and intrinsic renal disease management are crucial for improving patients’ survival. Complications should be foreseen and prevented, looking carefully at basic physical examination, weight and blood pressure monitoring, and blood, urine urea and electrolytes measurement.
Literatur
1.
Zurück zum Zitat Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527–39.CrossRefPubMed Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527–39.CrossRefPubMed
2.
Zurück zum Zitat Gil P, Justo S, Castilla MA, Criado C, Caramelo C. Cardio-renal insufficiency: the search for management strategies. Curr Opin Nephrol Hypertens. 2005;14:442–7.CrossRefPubMed Gil P, Justo S, Castilla MA, Criado C, Caramelo C. Cardio-renal insufficiency: the search for management strategies. Curr Opin Nephrol Hypertens. 2005;14:442–7.CrossRefPubMed
3.
Zurück zum Zitat Boerrigter G, Burnett JC Jr. Cardiorenal syndrome in decompensated heart failure: prognostic and therapeutic implications. Curr Heart Fail Rep. 2004;1:113–20.CrossRefPubMed Boerrigter G, Burnett JC Jr. Cardiorenal syndrome in decompensated heart failure: prognostic and therapeutic implications. Curr Heart Fail Rep. 2004;1:113–20.CrossRefPubMed
4.
Zurück zum Zitat Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203–10.PubMed Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203–10.PubMed
5.
Zurück zum Zitat Kearney MT, Fox KA, Lee AJ, Prescott RJ, Shah AM, Batin PD, et al. Predicting death due to progressive heart failure in patients with mild to-moderate chronic heart failure. J Am Coll Cardiol. 2002;40:1801–8.CrossRefPubMed Kearney MT, Fox KA, Lee AJ, Prescott RJ, Shah AM, Batin PD, et al. Predicting death due to progressive heart failure in patients with mild to-moderate chronic heart failure. J Am Coll Cardiol. 2002;40:1801–8.CrossRefPubMed
6.
Zurück zum Zitat Dumaine R, Collet JP, Tanguy ML, Mansencal N, Dubois-Randé JL, Henry P, et al. Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study). Am J Cardiol. 2004;94:1543–7.CrossRefPubMed Dumaine R, Collet JP, Tanguy ML, Mansencal N, Dubois-Randé JL, Henry P, et al. Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study). Am J Cardiol. 2004;94:1543–7.CrossRefPubMed
7.
Zurück zum Zitat Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296:1377–84.CrossRefPubMed Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296:1377–84.CrossRefPubMed
8.
Zurück zum Zitat Krumholz HM, Chen YT, Vaccarino V, Wang Y, Radford MJ, Bradford WD, et al. Correlates and impact on outcomes of worsening renal function in patients >65 years of age with heart failure. Am J Cardiol. 2000;85:1110–3.CrossRefPubMed Krumholz HM, Chen YT, Vaccarino V, Wang Y, Radford MJ, Bradford WD, et al. Correlates and impact on outcomes of worsening renal function in patients >65 years of age with heart failure. Am J Cardiol. 2000;85:1110–3.CrossRefPubMed
9.
Zurück zum Zitat Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, et al. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24:442–63.CrossRefPubMed Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, et al. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24:442–63.CrossRefPubMed
10.
Zurück zum Zitat Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Failure National Registry (ADHERE). Am Heart J. 2005;149:209–16.CrossRefPubMed Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Failure National Registry (ADHERE). Am Heart J. 2005;149:209–16.CrossRefPubMed
11.
Zurück zum Zitat Forman DE, Butler J, Wang Y, Abraham WT, O’Connor CM, Gottlieb SS, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61–7.CrossRefPubMed Forman DE, Butler J, Wang Y, Abraham WT, O’Connor CM, Gottlieb SS, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61–7.CrossRefPubMed
12.
Zurück zum Zitat Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ, For the ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572–80.CrossRefPubMed Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ, For the ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572–80.CrossRefPubMed
13.
Zurück zum Zitat Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, et al. The association among renal insufficiency, pharmacotherapy and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol. 2004;44:1587–91.CrossRefPubMed Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, et al. The association among renal insufficiency, pharmacotherapy and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol. 2004;44:1587–91.CrossRefPubMed
14.
Zurück zum Zitat Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47:1987–96.CrossRefPubMed Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006;47:1987–96.CrossRefPubMed
15.
Zurück zum Zitat Grigorian Shamagian L, Varela Román A, Pedreira Pérez M, Gómez Otero I, Virgós Lamela A, González-Juanatey JR. Renal failure is an independent predictor of mortality in hospitalized heart failure patients and is associated with a worse cardiovascular risk profile. Rev Esp Cardiol. 2006;59:99–108.CrossRefPubMed Grigorian Shamagian L, Varela Román A, Pedreira Pérez M, Gómez Otero I, Virgós Lamela A, González-Juanatey JR. Renal failure is an independent predictor of mortality in hospitalized heart failure patients and is associated with a worse cardiovascular risk profile. Rev Esp Cardiol. 2006;59:99–108.CrossRefPubMed
16.
Zurück zum Zitat Cotter G, Moshkovitz Y, Milovanov O, Salah A, Blatt A, Krakover R, et al. Acute heart failure: a novel approach to its pathogenesis and treatment. Eur J Heart Fail. 2002;4:227–34.CrossRefPubMed Cotter G, Moshkovitz Y, Milovanov O, Salah A, Blatt A, Krakover R, et al. Acute heart failure: a novel approach to its pathogenesis and treatment. Eur J Heart Fail. 2002;4:227–34.CrossRefPubMed
17.
Zurück zum Zitat Brewster UC, Setaro JF, Perazella MA. The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci. 2003;326:15–24.CrossRefPubMed Brewster UC, Setaro JF, Perazella MA. The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci. 2003;326:15–24.CrossRefPubMed
18.
Zurück zum Zitat Epstein BJ. Elevations in serum creatinine concentration: concerning or reassuring? Pharmacotherapy. 2004;24:697–702.CrossRefPubMed Epstein BJ. Elevations in serum creatinine concentration: concerning or reassuring? Pharmacotherapy. 2004;24:697–702.CrossRefPubMed
19.
Zurück zum Zitat Sanchez V, Delgado JF, Morales JM, Tello R, Gómez MA, Escribano P, et al. Chronic cyclosporine induced nephrotoxicity in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine. Transplant Proc. 2004;36:2823–5.CrossRefPubMed Sanchez V, Delgado JF, Morales JM, Tello R, Gómez MA, Escribano P, et al. Chronic cyclosporine induced nephrotoxicity in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine. Transplant Proc. 2004;36:2823–5.CrossRefPubMed
20.
Zurück zum Zitat Yoshida H, Yashiro M, Liang P, Muso E, Takeuchi E, Shimada T, et al. Mesangiolytic glomerulopathy in severe congestive heart failure. Kidney Int. 1998;53:880–91.CrossRefPubMed Yoshida H, Yashiro M, Liang P, Muso E, Takeuchi E, Shimada T, et al. Mesangiolytic glomerulopathy in severe congestive heart failure. Kidney Int. 1998;53:880–91.CrossRefPubMed
21.
Zurück zum Zitat Silverberg D, Wexler D, Blum M, Schwartz D, Iaina A. The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens. 2004;13:163–70.CrossRefPubMed Silverberg D, Wexler D, Blum M, Schwartz D, Iaina A. The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens. 2004;13:163–70.CrossRefPubMed
22.
Zurück zum Zitat Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension. 2004;43:699–706.CrossRefPubMed Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension. 2004;43:699–706.CrossRefPubMed
23.
Zurück zum Zitat Firth JD, Raine AE, Ledingham JG. Raised venous pressure: a direct cause of renal sodium retention in oedema? Lancet. 1988;1:1033–5.CrossRefPubMed Firth JD, Raine AE, Ledingham JG. Raised venous pressure: a direct cause of renal sodium retention in oedema? Lancet. 1988;1:1033–5.CrossRefPubMed
24.
Zurück zum Zitat Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35:681–9.CrossRefPubMed Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35:681–9.CrossRefPubMed
25.
Zurück zum Zitat Krumholz HM, Chen Y-T, Wang Y, Vaccarino V, Radford MJ, Horwitz RI. Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J. 2000;139:72–7.CrossRefPubMed Krumholz HM, Chen Y-T, Wang Y, Vaccarino V, Radford MJ, Horwitz RI. Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J. 2000;139:72–7.CrossRefPubMed
26.
Zurück zum Zitat Akhter MW, Aronson D, Bitar F, Khan S, Singh H, Singh RP, et al. Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. Am J Cardiol. 2004;94:957–60.CrossRefPubMed Akhter MW, Aronson D, Bitar F, Khan S, Singh H, Singh RP, et al. Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. Am J Cardiol. 2004;94:957–60.CrossRefPubMed
27.
Zurück zum Zitat Bongartz LG, Cramer MJ, Braam B. The cardiorenal connection [letter]. Hypertension. 2004;43:e14.CrossRefPubMed Bongartz LG, Cramer MJ, Braam B. The cardiorenal connection [letter]. Hypertension. 2004;43:e14.CrossRefPubMed
28.
Zurück zum Zitat Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol. 1992;262:E763–78.PubMed Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol. 1992;262:E763–78.PubMed
29.
Zurück zum Zitat Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141–8.PubMed Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141–8.PubMed
30.
Zurück zum Zitat Hornig B, Landmesser U, Kohler C, Ahlersmann D, Spiekermann S, Christoph A, et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation. 2001;103:799–805.PubMed Hornig B, Landmesser U, Kohler C, Ahlersmann D, Spiekermann S, Christoph A, et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation. 2001;103:799–805.PubMed
31.
Zurück zum Zitat Leineweber K, Heinroth-Hoffmann I, Pönicke K, Abraham G, Osten B, Brodde OE. Cardiac beta adrenoceptor desensitization due to increased beta-adrenoceptor kinase activity in chronic uremia. J Am Soc Nephrol. 2002;13:117–24.PubMed Leineweber K, Heinroth-Hoffmann I, Pönicke K, Abraham G, Osten B, Brodde OE. Cardiac beta adrenoceptor desensitization due to increased beta-adrenoceptor kinase activity in chronic uremia. J Am Soc Nephrol. 2002;13:117–24.PubMed
32.
Zurück zum Zitat Bleeke T, Zhang H, Madamanchi N, Patterson C, Faber JE. Catecholamine-induced vascular wall growth is dependent on generation of reactive oxygen species. Circ Res. 2004;94:37–45.CrossRefPubMed Bleeke T, Zhang H, Madamanchi N, Patterson C, Faber JE. Catecholamine-induced vascular wall growth is dependent on generation of reactive oxygen species. Circ Res. 2004;94:37–45.CrossRefPubMed
33.
Zurück zum Zitat Silverberg DS, Wexler D, Blum M, Wollman Y, Schwartz D, Sheps D, et al. The interaction between heart failure, renal failure and anemia—the cardio-renal anemia syndrome. Blood Purif. 2004;22:277–84.CrossRefPubMed Silverberg DS, Wexler D, Blum M, Wollman Y, Schwartz D, Sheps D, et al. The interaction between heart failure, renal failure and anemia—the cardio-renal anemia syndrome. Blood Purif. 2004;22:277–84.CrossRefPubMed
34.
Zurück zum Zitat Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737–44.CrossRefPubMed Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737–44.CrossRefPubMed
35.
Zurück zum Zitat Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999;34:125–34.CrossRefPubMed Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999;34:125–34.CrossRefPubMed
36.
Zurück zum Zitat Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, et al. Renal insufficiency and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol. 2001;12:218–25.PubMed Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, et al. Renal insufficiency and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol. 2001;12:218–25.PubMed
37.
Zurück zum Zitat Ikram H, Chan W, Espiner EA, Nicholls MG. Haemodynamic and hormone responses to acute and chronic furosemide therapy in congestive heart failure. Clin Sci. 1980;59:443–9.PubMed Ikram H, Chan W, Espiner EA, Nicholls MG. Haemodynamic and hormone responses to acute and chronic furosemide therapy in congestive heart failure. Clin Sci. 1980;59:443–9.PubMed
38.
Zurück zum Zitat Heywood JT. Combining nesiritide with high-dose diuretics may increase the risk of increased serum creatinine. J Card Fail. 2005;11(Suppl):S154. Heywood JT. Combining nesiritide with high-dose diuretics may increase the risk of increased serum creatinine. J Card Fail. 2005;11(Suppl):S154.
39.
Zurück zum Zitat Mehta RL, Pascual MT, Soroko S, Chertow GM, For the PICARD Study Group. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA. 2002;288:2547–53.CrossRefPubMed Mehta RL, Pascual MT, Soroko S, Chertow GM, For the PICARD Study Group. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA. 2002;288:2547–53.CrossRefPubMed
40.
Zurück zum Zitat Kubo SH, Clark M, Laragh JH, Borer JS, Cody RJ. Identification of normal neurohormonal activity in mild congestive heart failure and stimulating effect of upright posture and diuretics. Am J Cardiol. 1987;60:1322–8.CrossRefPubMed Kubo SH, Clark M, Laragh JH, Borer JS, Cody RJ. Identification of normal neurohormonal activity in mild congestive heart failure and stimulating effect of upright posture and diuretics. Am J Cardiol. 1987;60:1322–8.CrossRefPubMed
41.
Zurück zum Zitat Neuberg GW, Miller AB, O’Connor CM, Belkin RN, Carson PE, Cropp AB, et al. Prospective Randomized Amlodipine Survival Evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144:31–8.CrossRefPubMed Neuberg GW, Miller AB, O’Connor CM, Belkin RN, Carson PE, Cropp AB, et al. Prospective Randomized Amlodipine Survival Evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144:31–8.CrossRefPubMed
43.
Zurück zum Zitat Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705–8.CrossRefPubMed Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705–8.CrossRefPubMed
44.
Zurück zum Zitat Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vasopressin receptor antagonists. Drugs. 2007;67:847–58.CrossRefPubMed Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vasopressin receptor antagonists. Drugs. 2007;67:847–58.CrossRefPubMed
45.
Zurück zum Zitat Verbalis JG. AVP receptor antagonists as aquaretics: review and assessment of clinical data. Cleve Clin J Med. 2006;73(Suppl 3):S24–33.CrossRefPubMed Verbalis JG. AVP receptor antagonists as aquaretics: review and assessment of clinical data. Cleve Clin J Med. 2006;73(Suppl 3):S24–33.CrossRefPubMed
46.
Zurück zum Zitat Gheorghiade M, Gattis WA, O’Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963–71.CrossRefPubMed Gheorghiade M, Gattis WA, O’Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963–71.CrossRefPubMed
47.
Zurück zum Zitat Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:1332–43.CrossRefPubMed Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:1332–43.CrossRefPubMed
48.
Zurück zum Zitat Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation. 2001;104:1985–91.CrossRefPubMed Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation. 2001;104:1985–91.CrossRefPubMed
49.
Zurück zum Zitat Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and vasodilator therapy during heart failure hospitalization in the ESCAPE Trial. Circulation. 2004;110(Suppl 3):III-515. Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and vasodilator therapy during heart failure hospitalization in the ESCAPE Trial. Circulation. 2004;110(Suppl 3):III-515.
50.
Zurück zum Zitat DiDomenico RJ, Park HY, Southworth MR, Eyrich HM, Lewis RK, Finley JM, et al. Guidelines for acute decompensated heart failure treatment. Ann Pharmacother. 2004;38:649–60.CrossRefPubMed DiDomenico RJ, Park HY, Southworth MR, Eyrich HM, Lewis RK, Finley JM, et al. Guidelines for acute decompensated heart failure treatment. Ann Pharmacother. 2004;38:649–60.CrossRefPubMed
51.
Zurück zum Zitat Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH, et al. In-hospital mortality in patients with acute decompensated heart failure treated with intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46:57–64.CrossRefPubMed Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH, et al. In-hospital mortality in patients with acute decompensated heart failure treated with intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46:57–64.CrossRefPubMed
52.
Zurück zum Zitat Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1903–12.CrossRefPubMed Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1903–12.CrossRefPubMed
53.
Zurück zum Zitat Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297:1883–91.CrossRefPubMed Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297:1883–91.CrossRefPubMed
54.
Zurück zum Zitat Chatterjee K, Parmley WW, Cohn JN, Levine TB, Awan NA, Mason DT, et al. A cooperative multicenter study of captopril in congestive heart failure: hemodynamic effects and long-term response. Am Heart J. 1985;110:439–47.CrossRefPubMed Chatterjee K, Parmley WW, Cohn JN, Levine TB, Awan NA, Mason DT, et al. A cooperative multicenter study of captopril in congestive heart failure: hemodynamic effects and long-term response. Am Heart J. 1985;110:439–47.CrossRefPubMed
55.
Zurück zum Zitat Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med. 1987;317:799–804.PubMedCrossRef Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med. 1987;317:799–804.PubMedCrossRef
56.
Zurück zum Zitat Marcus LS, Hart D, Packer M, Yushak M, Medina N, Danziger RS, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: a double-blind, placebo-controlled, randomized crossover trial. Circulation. 1996;94:3184–9.PubMed Marcus LS, Hart D, Packer M, Yushak M, Medina N, Danziger RS, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: a double-blind, placebo-controlled, randomized crossover trial. Circulation. 1996;94:3184–9.PubMed
57.
Zurück zum Zitat Januzzi KL. Natriurtic peptide testing: a window into the diagnosis and prognosis of heart failure. Cleve Clin J Med. 2006;73:149–57.CrossRefPubMed Januzzi KL. Natriurtic peptide testing: a window into the diagnosis and prognosis of heart failure. Cleve Clin J Med. 2006;73:149–57.CrossRefPubMed
58.
Zurück zum Zitat Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, et al. BG 9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348–53.CrossRefPubMed Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, et al. BG 9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348–53.CrossRefPubMed
59.
Zurück zum Zitat Elkayam U, Singh H, Akhter MW, et al. Effects of intravenous nesiritide on renal hemodynamics in patients with congestive heart failure. J Card Fail. 2004;10(Suppl 4):S88.CrossRef Elkayam U, Singh H, Akhter MW, et al. Effects of intravenous nesiritide on renal hemodynamics in patients with congestive heart failure. J Card Fail. 2004;10(Suppl 4):S88.CrossRef
60.
Zurück zum Zitat Abraham WT. Serum creatinine elevations in patients receiving nesiritide are related to starting dose. J Card Fail. 2005;11(Suppl):S156. Abraham WT. Serum creatinine elevations in patients receiving nesiritide are related to starting dose. J Card Fail. 2005;11(Suppl):S156.
61.
Zurück zum Zitat Elkayam U. Nesiritide may diminish the increased acute mortality risk associated with worsening renal function. Circulation. 2005;112(Suppl II):676. Elkayam U. Nesiritide may diminish the increased acute mortality risk associated with worsening renal function. Circulation. 2005;112(Suppl II):676.
62.
Zurück zum Zitat Armstrong PW, Rouleau JL. A Canadian context for the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF) trial. Can J Cardiol. 2008;24(Suppl B):30B–2B.PubMed Armstrong PW, Rouleau JL. A Canadian context for the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF) trial. Can J Cardiol. 2008;24(Suppl B):30B–2B.PubMed
63.
Zurück zum Zitat Dohadwala MM, Givertz MM. Role of adenosine antagonism in the cardiorenal syndrome. Cardiovasc Ther. 2008;26:276–86.CrossRefPubMed Dohadwala MM, Givertz MM. Role of adenosine antagonism in the cardiorenal syndrome. Cardiovasc Ther. 2008;26:276–86.CrossRefPubMed
64.
Zurück zum Zitat Witteles RM, Kao D, Christopherson D, Matsuda K, Vagelos RH, Schreiber D, et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol. 2007;50:1835–40.CrossRefPubMed Witteles RM, Kao D, Christopherson D, Matsuda K, Vagelos RH, Schreiber D, et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol. 2007;50:1835–40.CrossRefPubMed
65.
Zurück zum Zitat Ljungman S, Laragh JH, Cody RJ. Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs. 1990;39(Suppl 4):10–21.CrossRefPubMed Ljungman S, Laragh JH, Cody RJ. Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs. 1990;39(Suppl 4):10–21.CrossRefPubMed
66.
Zurück zum Zitat Packer M. Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition. Am J Cardiol. 1987;60:179–84.CrossRefPubMed Packer M. Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition. Am J Cardiol. 1987;60:179–84.CrossRefPubMed
67.
Zurück zum Zitat Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998;54:1283–9.CrossRefPubMed Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998;54:1283–9.CrossRefPubMed
68.
Zurück zum Zitat Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160:685–93.CrossRefPubMed Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160:685–93.CrossRefPubMed
69.
Zurück zum Zitat Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol. 1999;26(Suppl 56):18–24. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol. 1999;26(Suppl 56):18–24.
70.
Zurück zum Zitat Johnson AG. NSAIDs and increased blood pressure. What is the clinical significance? Drug Saf. 1997;17:277–89.CrossRefPubMed Johnson AG. NSAIDs and increased blood pressure. What is the clinical significance? Drug Saf. 1997;17:277–89.CrossRefPubMed
71.
Zurück zum Zitat Sandhu GK, Heyneman CA. Nephrotoxic potential of selective cyclooxygenase-2 inhibitors. Ann Pharmacother. 2004;38:700–4.CrossRefPubMed Sandhu GK, Heyneman CA. Nephrotoxic potential of selective cyclooxygenase-2 inhibitors. Ann Pharmacother. 2004;38:700–4.CrossRefPubMed
72.
Zurück zum Zitat Practice Guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 1996;84:732–47. Practice Guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology 1996;84:732–47.
74.
Zurück zum Zitat Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:1775–80.CrossRefPubMed Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:1775–80.CrossRefPubMed
75.
Zurück zum Zitat Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107:294–9.CrossRefPubMed Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107:294–9.CrossRefPubMed
76.
Zurück zum Zitat Cleland JG, Sullivan JT, Ball S, Horowitz JD, Agoram B, Rosser D, et al. Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation. J Cardiovasc Pharmacol. 2005;46:155–61.CrossRefPubMed Cleland JG, Sullivan JT, Ball S, Horowitz JD, Agoram B, Rosser D, et al. Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation. J Cardiovasc Pharmacol. 2005;46:155–61.CrossRefPubMed
77.
Zurück zum Zitat van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J. 2007;28:2208–16.CrossRefPubMed van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J. 2007;28:2208–16.CrossRefPubMed
78.
Zurück zum Zitat Ponikowski P, Anker SD, Szachniewicz J, Okonko D, Ledwidge M, Zymlinski R, et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure. A randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2007;49:753–62.CrossRefPubMed Ponikowski P, Anker SD, Szachniewicz J, Okonko D, Ledwidge M, Zymlinski R, et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure. A randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2007;49:753–62.CrossRefPubMed
79.
Zurück zum Zitat Parissis JT, Kourea K, Panou F, Farmakis D, Paraskevaidis I, Ikonomidis I, et al. Effects of darbepoetin α on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J. 2008;155:751.e1–7.CrossRef Parissis JT, Kourea K, Panou F, Farmakis D, Paraskevaidis I, Ikonomidis I, et al. Effects of darbepoetin α on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J. 2008;155:751.e1–7.CrossRef
80.
Zurück zum Zitat Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 2008;117:526–35.CrossRefPubMed Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B, Krum H, et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 2008;117:526–35.CrossRefPubMed
81.
Zurück zum Zitat Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, Keren G, et al. Iaina A The effect of correction of anaemia in diabetics and nondiabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant. 2003;18:141–6.CrossRefPubMed Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, Keren G, et al. Iaina A The effect of correction of anaemia in diabetics and nondiabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant. 2003;18:141–6.CrossRefPubMed
82.
Zurück zum Zitat Fazlibegović E, Hadziomerović M, Corić S, Babić E, Fazlibegović F. Erythropoietin in cardiorenal anemia syndrome. Bosn J Basic Med Sci. 2006;6:36–41.PubMed Fazlibegović E, Hadziomerović M, Corić S, Babić E, Fazlibegović F. Erythropoietin in cardiorenal anemia syndrome. Bosn J Basic Med Sci. 2006;6:36–41.PubMed
83.
Zurück zum Zitat Judith E. Mitchell. Emerging Role of Anemia in Heart Failure. Am J Cardiol. 2007;99(suppl):15D–20D. Judith E. Mitchell. Emerging Role of Anemia in Heart Failure. Am J Cardiol. 2007;99(suppl):15D–20D.
84.
Zurück zum Zitat Valles J, Santos MT, Aznar J, Martinez M, Moscardo A, Pinon M, et al. Platelet-erythrocyte interactions enhance alpha(IIb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo. Blood. 2002;99:3978–84.CrossRefPubMed Valles J, Santos MT, Aznar J, Martinez M, Moscardo A, Pinon M, et al. Platelet-erythrocyte interactions enhance alpha(IIb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo. Blood. 2002;99:3978–84.CrossRefPubMed
85.
Zurück zum Zitat Fuste B, Serradell M, Escolar G, Cases A, Mazzara R, Castillo R, et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost. 2002;88:678–85.PubMed Fuste B, Serradell M, Escolar G, Cases A, Mazzara R, Castillo R, et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost. 2002;88:678–85.PubMed
86.
Zurück zum Zitat Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis. 1999;33:821–8.CrossRefPubMed Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis. 1999;33:821–8.CrossRefPubMed
87.
Zurück zum Zitat IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis. 2001;37:S182–S238. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis. 2001;37:S182–S238.
88.
89.
Zurück zum Zitat Hampl H, Sternberg C, Berweck S, et al. Regression of left ventricular hypertrophy in hemodialysis patients is possible. Clin Nephrol. 2002;58(Suppl 1):S73–96.PubMed Hampl H, Sternberg C, Berweck S, et al. Regression of left ventricular hypertrophy in hemodialysis patients is possible. Clin Nephrol. 2002;58(Suppl 1):S73–96.PubMed
90.
Zurück zum Zitat Gouva C, Nikolopoulos P, Ioannidis JPA, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal functional: a randomized controlled trial. Kidney Int. 2004;66:753–60.CrossRefPubMed Gouva C, Nikolopoulos P, Ioannidis JPA, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal functional: a randomized controlled trial. Kidney Int. 2004;66:753–60.CrossRefPubMed
91.
Zurück zum Zitat Mix TC, Brenner RM, Cooper ME, de Zeeuw D, Ivanovich P, Levey AS, et al. Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J. 2005;149:408–13.CrossRefPubMed Mix TC, Brenner RM, Cooper ME, de Zeeuw D, Ivanovich P, Levey AS, et al. Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J. 2005;149:408–13.CrossRefPubMed
92.
Zurück zum Zitat Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–98.CrossRefPubMed Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–98.CrossRefPubMed
93.
Zurück zum Zitat Anker SD, Toto R. Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients. NDT Plus. 2009;2:i3–8.CrossRefPubMed Anker SD, Toto R. Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients. NDT Plus. 2009;2:i3–8.CrossRefPubMed
94.
Zurück zum Zitat Young JB, Anand IS, Diaz R et al. Reduction of events with darbepoetin alfa in heart failure (RED-HF)TM Trial [abstract 950169]. Presented at 10th Annual Scientific Meeting of the Heart Failure Society of America, Seattle, Washington, 10–13 September 2006. Young JB, Anand IS, Diaz R et al. Reduction of events with darbepoetin alfa in heart failure (RED-HF)TM Trial [abstract 950169]. Presented at 10th Annual Scientific Meeting of the Heart Failure Society of America, Seattle, Washington, 10–13 September 2006.
95.
Zurück zum Zitat Marenzi G, Lauri G, Grazi M, Assanelli E, Campodonico J, Agostoni P. Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol. 2001;38:963–8.CrossRefPubMed Marenzi G, Lauri G, Grazi M, Assanelli E, Campodonico J, Agostoni P. Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol. 2001;38:963–8.CrossRefPubMed
96.
Zurück zum Zitat Guglin M, Polavaram L. Ultrafiltration in heart failure. Cardiol Rev. 2007;5:226–30.CrossRef Guglin M, Polavaram L. Ultrafiltration in heart failure. Cardiol Rev. 2007;5:226–30.CrossRef
97.
Zurück zum Zitat Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;6:675–83.CrossRef Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;6:675–83.CrossRef
98.
Zurück zum Zitat Ellis JH, Cohan RH. Reducing the risk of contrast-induced nephropathy: a prospective on the controversies. Am J Roentgenol. 2009;192:1544–9.CrossRef Ellis JH, Cohan RH. Reducing the risk of contrast-induced nephropathy: a prospective on the controversies. Am J Roentgenol. 2009;192:1544–9.CrossRef
99.
Zurück zum Zitat Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95:13–9.CrossRefPubMed Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95:13–9.CrossRefPubMed
100.
Zurück zum Zitat Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic pepetide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA. 2005;293:1609–16.CrossRefPubMed Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic pepetide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA. 2005;293:1609–16.CrossRefPubMed
Metadaten
Titel
Cardiorenal syndrome: still not a defined entity
verfasst von
Carlo Longhini
Christian Molino
Fabio Fabbian
Publikationsdatum
01.02.2010
Verlag
Springer Japan
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 1/2010
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-009-0257-4

Weitere Artikel der Ausgabe 1/2010

Clinical and Experimental Nephrology 1/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Auf Antibiotika verzichten? Was bei unkomplizierter Zystitis hilft

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Klimaschutz beginnt bei der Wahl des Inhalators

14.05.2024 Klimawandel Podcast

Auch kleine Entscheidungen im Alltag einer Praxis können einen großen Beitrag zum Klimaschutz leisten. Die neue Leitlinie zur "klimabewussten Verordnung von Inhalativa" geht mit gutem Beispiel voran, denn der Wechsel vom klimaschädlichen Dosieraerosol zum Pulverinhalator spart viele Tonnen CO2. Leitlinienautor PD Dr. Guido Schmiemann erklärt, warum nicht nur die Umwelt, sondern auch Patientinnen und Patienten davon profitieren.

Zeitschrift für Allgemeinmedizin, DEGAM

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.